Theoretical aspects of weight loss in patients with cancer. Possible importance of pyruvate dehydrogenase.
In the analysis of weight loss in cancer patients, consideration must be given to decreased caloric intake, increased caloric expenditure and abnormal losses of calories. When these factors do not adequately explain the degree of weight loss, this may be due to a specific loss of lean body mass, as the caloric density of muscle is much less than that of fat. The key enzyme for the protection of lean body mass in hypocaloric states is pyruvate dehydrogenase (PDH). During fasting, fast oxidation in host tissues leads to inactivation of PDH, preventing irreversible loss of pyruvate precursors which would have to be replaced by protein breakdown. A tumor in which PDH activity remains high in the fasting state would cause loss of lean body mass in the host. This report suggests that this phenomenon may be important in certain patients with cancer cachexia.
D000596:Amino Acids / Q000378:metabolism; D001835:Body Weight; D002100:Cachexia / Q000209:etiology / Q000378:metabolism*; D050260:Carbohydrate Metabolism; D002149:Energy Intake; D004734:Energy Metabolism; D006003:Glycogen / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism; D009369:Neoplasms / Q000150:complications / Q000378:metabolism*; D011506:Proteins / Q000378:metabolism; D011768:Pyruvate Dehydrogenase Complex / Q000378:metabolism*
D000596:Amino Acids; D011506:Proteins; D011768:Pyruvate Dehydrogenase Complex; D006003:Glycogen